KemPharm, Inc.

134 articles with KemPharm, Inc.

• KemPharm to Report Second Quarter 2021 Results

  8/5/2021

  KemPharm today announced the Company will host a Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, August 12, 2021, 4:30 p.m. ET

• KemPharm Announces U.S. Launch of Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules) by Corium, Inc.

  7/21/2021

  KemPharm, Inc. today announced the U.S. commercial launch of AZSTARYS™

• KemPharm Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement - June 18, 2021

  6/18/2021

  KemPharm, Inc. announced it has entered into agreements with certain of its holders of its existing warrants exercisable for 6,117,509 shares of its common stock, in the aggregate, pursuant to which such holders agreed to exercise their warrants for cash in exchange for the Company’s agreement to issue in a private placement new warrants to purchase up to 1,529,379 shares of its common stock.

• KemPharm Issues Letter to Shareholders

  6/16/2021

  KemPharm, Inc.today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, has issued a Letter to Shareholders in connection with the Company’s 2021 Annual Meeting of Stockholders to be held on June 17, 2021.  

• KemPharm to be Added to Russell 2000® and Russell 3000® Indexes Effective June 28, 2021

  6/9/2021

  KemPharm, Inc., a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced its expected addition to the broad-market Russell 3000® Index and the Russell 2000® Index in accordance with the 2021 Russell indexes annual reconstitution.

• KemPharm Executives to Participate in Panel Discussions During Upcoming June 2021 Conferences

  6/3/2021

  KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm, will participate in a panel discussion on the regulatory environment during the COVID-19 pandemic at the Consero Global IP Management and IP Life Sciences Virtual Forum taking place June 7-8, 2021.

• KemPharm, Inc. Announces Orange Book Listing for Six Patents Covering Serdexmethylphenidate (SDX) and Confirmation of NCE Status

  5/26/2021

  SDX is KemPharm’s proprietary prodrug of d-methylphenidate (d-MPH) and the primary active pharmaceutical ingredient (API) in AZSTARYS™

• KemPharm Announces Serdexmethylphenidate (SDX) Has Been Classified as a Schedule IV Controlled Substance by the DEA

  5/7/2021

  KP879, KemPharm’s Lead Product Candidate Based on SDX and Intended for the Treatment of Stimulant Use Disorder (SUD), Could Be Schedule IV, If Approved by the FDA

• KemPharm Confirms Receipt of $10 Million Milestone Payment for FDA Approval of AZSTARYS™ Per License Agreement with Affiliate of Gurnet Point Capital

  4/21/2021

  KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced receipt of a regulatory milestone payment of $10 million for the FDA approval of AZSTARYS™ in accordance with the recently amended definitive collaboration and license agreement with Commave Therapeutics,

• KemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS™

  4/8/2021

  KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced an amendment to the definitive collaboration and license agreement (the License Agreement) with an affiliate of Gurnet Point Capital (GPC), a private investment firm focused on the life sciences and medical technology sectors

• KemPharm Reports Fourth Quarter and Full-Year 2020 Financial Results

  3/11/2021

  KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today reported its financial results for the fourth quarter and year ended December 31, 2020.

• KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results

  3/9/2021

  Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, March 11, 2021, 4:30 p.m. ET

• KemPharm to Present at the 33rd Annual Roth Conference

  3/4/2021

  KemPharm, Inc., a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will present at the 33rd Annual Roth Conference being held virtually from March 15-17, 2021.

• 

  KemPharm Snags Approval for ADHD Prodrug

  3/4/2021

  KemPharm announced this week that the U.S. Food and Drug Administration has approved its novel ADHD drug for use in patients six years and older.  

• KemPharm Announces FDA Approval of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD

  3/3/2021

  Conference Call and Live Audio Webcast Scheduled for Tomorrow, Wednesday, March 3, at 8:30 a.m. ET

• 

  Approved! FDA Grants IND Clearance to Three More Candidates Today

  1/28/2021

  The FDA is on a roll granting approvals. Three companies announced IND updates today. 

• KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the 2021 APSARD Virtual Conference

  1/14/2021

  KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that research involving KP415 and serdexmethylphenidate (SDX) will be featured in an oral symposium and three poster presentations during the 2021 American Professional Society of ADHD and Related Disorders (APSARD) Vi

• KemPharm Announces 1-for-16 Reverse Stock Split

  12/23/2020

  KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company's Board of Directors has approved a 1-for-16 reverse stock split of its shares of common stock (“Reverse Stock Split”). KemPharm’s stockholders granted authority to the Board of Directors to effect this Reverse Stock Split of KemPharm’s common stock at the Special Meeting of Stock

• KemPharm Participates in KP415 Late-Cycle Communication Meeting with FDA

  12/2/2020

  CELEBRATION, Fla., Dec. 02, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company participated in a late-cycle communication meeting on December 1, 2020, with the U.S. Food and Drug Administration (FDA, or the Agency) regarding the ongoing review of the New Drug Application (NDA) for KP415, KemPharm’s investigational product candidate for the treatment of atten

• KemPharm Provides Update on Development Pipeline

  11/23/2020

  IND for KP879 Expected to be Filed Before Year-End 2020; New Prodrug CandidateAdded to Pipeline,Targeting Rare CNS Disease, Idiopathic Hypersomnia (IH)